Article Text

Download PDFPDF
▾ Evolocumab as an adjunct to statins for CVD

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The injectable monoclonal antibody evolocumab has been shown to reduce low-density lipoprotein (LDL) cholesterol levels by more than 50% in patients with hypercholesterolaemia.1 However, evidence on its effect on cardiovascular events is limited, partly because trials have focussed on a primary outcome of reduction in LDL cholesterol but also as a result of low numbers of cardiovascular events in trials.2,3 A large randomised double-blind placebo-controlled trial has assessed the effectiveness of evolocumab in reducing major cardiovascular events using a composite outcome of cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina, or coronary revascularisation.3

The trial (1,272 …

View Full Text